Ph I 5-day Temozolomide + O6-BG in Treatment of Pts w Recurrent / Progressive GBM
Status:
Completed
Trial end date:
2008-07-01
Target enrollment:
Participant gender:
Summary
Primary objectives To determine maxi tolerated dose of Temodar® in combo w O6-benzylguanine
administered for 5 consecutive days in pts w progressive/recurrent GBM To characterize
toxicity associated w Temodar® in combo w O6-BG administered for 5 consecutive days in pts w
progressive/recurrent GBM To determine Neulasta®-supported MTD defined as the MTD of Temodar®
in combo with O6-BG administered for 5 days while receiving Neulasta® once per treatment
cycle between days 7 & 14 in pts w progressive/recurrent GBM To obtain preliminary response
rates of Temodar® in combo w O6-BG administered for 5 consecutive days in pts w
progressive/recurrent GBM